PMID- 37432669
OWN - NLM
STAT- MEDLINE
DCOM- 20231005
LR  - 20231010
IS  - 1502-7686 (Electronic)
IS  - 0036-5513 (Linking)
VI  - 83
IP  - 6
DP  - 2023 Oct
TI  - The prognostic impact of inflammation in patients with decompensated acute heart 
      failure, as assessed using the pan-immune inflammation value (PIV).
PG  - 371-378
LID - 10.1080/00365513.2023.2233890 [doi]
AB  - There is increasing evidence that composite scores based on blood counts, which 
      are reflectors of uncontrolled inflammation in the development and progression of 
      heart failure, can be used as prognostic biomarkers in heart failure patients. 
      The prognostic effects of pan-immune inflammation (PIV) as an independent 
      predictor of in-hospital mortality in patients with acute heart failure (AHF) 
      were evaluated based on this evidence. The data of 640 consecutive patients 
      hospitalized for New York Heart Association (NYHA) class 2-3-4 AHF with reduced 
      ejection fraction were analyzed and 565 patients were included after exclusion. 
      The primary outcome was in hospital all-cause death. Secondary outcomes were 
      defined as the following in-hospital events: Acute kidney injury (AKI), malignant 
      arrhythmias, acute renal failure (ARF) and stroke. The PIV was computed using 
      hemogram parameters such as lymphocytes, neutrophils, monocytes and platelets. 
      Patients were categorized as low or high PIV group according to the median value, 
      which was 382.8. A total of 81 (14.3%) in-hospital deaths, 31 (5.4%) AKI, 34 (6%) 
      malignant arrhythmias, 60 (10.6%) ARF and 11 (2%) strokes were reported. Patients 
      with high PIV had a higher in-hospital mortality rate than patients with low PIV 
      (OR: 1.51, 95% CI, 1.26-1.80, p < 0.001). Incorporating PIV into the full model 
      significantly improved model performance (odds ratio X(2), p < 0.001) compared to 
      the baseline model constructed with other inflammatory markers. PIV is a potent 
      predictor of prognosis with better performance than other well-known inflammatory 
      markers for patients with AHF.
FAU - Inan, Duygu
AU  - Inan D
AUID- ORCID: 0000-0003-3921-6469
AD  - Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, 
      Turkey.
FAU - Erdogan, Aslan
AU  - Erdogan A
AD  - Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, 
      Turkey.
FAU - Pay, Levent
AU  - Pay L
AD  - Department of Cardiology, Ardahan State Hospital, Ardahan, Turkey.
FAU - Genc, Duygu
AU  - Genc D
AD  - Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, 
      Turkey.
FAU - Demirtola, Ayse Irem
AU  - Demirtola AI
AD  - Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, 
      Turkey.
FAU - Yildiz, Ufuk
AU  - Yildiz U
AD  - Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, 
      Turkey.
FAU - Guler, Ahmet
AU  - Guler A
AD  - Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, 
      Turkey.
FAU - Tekkesin, Ahmet Ilker
AU  - Tekkesin AI
AD  - Department of Cardiology, Basaksehir Cam & Sakura City Hospital, Istanbul, 
      Turkey.
FAU - Karagoz, Ali
AU  - Karagoz A
AD  - Department of Cardiology, Istanbul Kosuyolu High Specialization Education and 
      Research Hospital, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20230711
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
SB  - IM
MH  - Humans
MH  - Prognosis
MH  - Acute Disease
MH  - *Heart Failure
MH  - Inflammation/complications
MH  - *Acute Kidney Injury
OTO - NOTNLM
OT  - acute heart failure
OT  - better performance
OT  - in-hospital mortality
OT  - pan-immune inflammation value (PIV)
OT  - prognostic predictor
EDAT- 2023/07/11 13:10
MHDA- 2023/10/05 06:44
CRDT- 2023/07/11 11:23
PHST- 2023/10/05 06:44 [medline]
PHST- 2023/07/11 13:10 [pubmed]
PHST- 2023/07/11 11:23 [entrez]
AID - 10.1080/00365513.2023.2233890 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2023 Oct;83(6):371-378. doi: 
      10.1080/00365513.2023.2233890. Epub 2023 Jul 11.